Transcend Capital Advisors LLC Purchases Shares of 1,286 IQVIA Holdings Inc. $IQV

Transcend Capital Advisors LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,286 shares of the medical research company’s stock, valued at approximately $203,000.

Several other large investors also recently made changes to their positions in IQV. Pacer Advisors Inc. increased its stake in shares of IQVIA by 5,036.1% in the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after purchasing an additional 854,732 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after acquiring an additional 798,534 shares in the last quarter. Nordea Investment Management AB boosted its holdings in shares of IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after acquiring an additional 606,391 shares in the last quarter. Hawk Ridge Capital Management LP bought a new position in shares of IQVIA in the first quarter valued at approximately $77,096,000. Finally, Nuveen LLC bought a new position in shares of IQVIA in the first quarter valued at approximately $76,328,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 0.0%

Shares of NYSE:IQV opened at $216.43 on Friday. The stock has a market capitalization of $36.86 billion, a price-to-earnings ratio of 29.69, a PEG ratio of 2.43 and a beta of 1.32. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $225.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.84 and a current ratio of 0.70. The company has a 50 day moving average price of $197.12 and a 200 day moving average price of $173.77.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Mizuho increased their price objective on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. Stifel Nicolaus raised their target price on shares of IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, UBS Group raised their target price on shares of IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $241.41.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.